Literature DB >> 7661345

Renal function in patients with high serum fluoride concentrations after prolonged sevoflurane anesthesia.

H Higuchi1, H Sumikura, S Sumita, S Arimura, F Takamatsu, M Kanno, T Satoh.   

Abstract

BACKGROUND: In studies of methoxyflurane-induced nephrotoxicity, renal-concentrating impairment has been observed only when serum inorganic fluoride concentrations exceed 50 microM. Prolonged sevoflurane anesthesia can result in serum inorganic fluoride concentrations in excess of 50 microM. The authors compared renal function after prolonged sevoflurane anesthesia with that after isoflurane anesthesia. In addition, they measured urinary excretion of N-acetyl-beta-glucosaminidase (NAG), a sensitive index of renal tubular damage, during the 3-day period after anesthesia.
METHODS: Thirty-four healthy patients who underwent either sevoflurane (23 patients) or isoflurane (11 patients) anesthesia at a total gas flow of 61/min for orthopedic surgery scheduled to last at least 5 h were studied. At 16.5 h after cessation of anesthesia, patients were administered 10 units of vasopressin and urine was collected frequently thereafter for evaluation of urinary osmolality. In addition, urinary excretion of NAG was measured before and on days 1-3 after anesthesia. Based on whether peak fluoride concentrations exceeded 50 microM, 23 patients anesthetized with sevoflurane were assigned to a sevofluranehigh group (> 50 microM) or a sevofluranelow (< 50 microM) group.
RESULTS: The eight patients in the sevofluranehigh group had a mean peak fluoride concentration of 57.5 +/- 4.3 microM. A significant, albeit weak, inverse correlation was found between peak fluoride concentration and maximal urinary osmolality after the injection of vasopressin (r = -0.42, P < 0.05). Mean maximum urinary osmolality tended to be lower in the sevofluranehigh group (681 +/- 60 mOsm/kg) than in the other two groups after administration of vasopressin, although the difference among the three groups did not quite reach a statistical significance (P = 0.068). One patient had a transient concentrating defect (maximum urinary osmolality = 390 mOsm/kg) on day 1 after anesthesia. Urinary excretion of NAG in both the sevofluranehigh and sevofluranelow groups was greater on days 2 and 3 after anesthesia than before anesthesia. The increase in urinary NAG excretion was dose related with sevoflurane, but there was no difference in results of routine laboratory renal tests on days 2 and 3 after anesthesia among the three groups.
CONCLUSIONS: The authors concluded that sevoflurane anesthesia results in increased serum fluoride concentration, a tendency toward decreased maximal ability to concentrate urine, and increased excretion of NAG. However, the increase in urinary NAG excretion was not indicative of clinically significant renal damage in these patients with no preexisting renal disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7661345     DOI: 10.1097/00000542-199509000-00003

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  11 in total

1.  New volatile anaesthetics in cardiovascular anaesthesia: one step forward, two steps back?

Authors:  I R Thomson
Journal:  Can J Anaesth       Date:  1996-09       Impact factor: 5.063

2.  Pharmacokinetics of fluoride in toddlers after application of 5% sodium fluoride dental varnish.

Authors:  Peter Milgrom; Donald M Taves; Amy S Kim; Gene E Watson; Jeremy A Horst
Journal:  Pediatrics       Date:  2014-08-18       Impact factor: 7.124

3.  Urinary sevoflurane and hexafluoro-isopropanol as biomarkers of low-level occupational exposure to sevoflurane.

Authors:  Antonio Accorsi; Barbara Morrone; Irene Domenichini; Simona Valenti; Giovanni Battista Raffi; Francesco Saverio Violante
Journal:  Int Arch Occup Environ Health       Date:  2005-04-30       Impact factor: 3.015

4.  Effect of sevoflurane anesthesia on the severity of renal histopathologic changes in rabbits pretreated with gentamicin: A controlled, investigator-blinded, experimental study.

Authors:  Azize Bestas; Mustafa Kemal Bayar; Nusret Akpolat; Mehmet Nihat Okuducu
Journal:  Curr Ther Res Clin Exp       Date:  2006-11

Review 5.  Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 6.  Renal toxicity with sevoflurane: a storm in a teacup?

Authors:  B A Gentz; T P Malan
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of sevoflurane.

Authors:  M Behne; H J Wilke; S Harder
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

8.  Effect of sevoflurane on grafted kidney function in renal transplantation.

Authors:  Jin Ha Park; Jae Hoon Lee; Dong Jin Joo; Ki Jun Song; Yu Seun Kim; Bon-Nyeo Koo
Journal:  Korean J Anesthesiol       Date:  2012-06-19

Review 9.  The impact of sevoflurane anesthesia on postoperative renal function: a systematic review and meta-analysis of randomized-controlled trials.

Authors:  Rakesh V Sondekoppam; Karim H Narsingani; Trent A Schimmel; Brie M McConnell; Karen Buro; Timur J-P Özelsel
Journal:  Can J Anaesth       Date:  2020-08-18       Impact factor: 6.713

10.  Sevoflurane, a sigh of relief in COVID-19?

Authors:  Gertrude J Nieuwenhuijs-Moeke; Jayant S Jainandunsing; Michel M R F Struys
Journal:  Br J Anaesth       Date:  2020-05-01       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.